VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Rezolute Executive Compensation (FY26)

RZLT · Executive and director compensation, fiscal 2022 to 2026
Chief executive, fiscal 2026
◇
Nevan Charles Elam
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Rezolute brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 1, 2026Latest filing (DEF 14A): October 21, 2026
3 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Rezolute brief$500Get the executive brief
Velarion Intel, one year, every company
153 figures on this page, cited to the filing that reported them. See the citations
What changed from fiscal 2025 to fiscal 2026
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Nevan Charles Elam: $2,851,109 → $5,711,410 (100.3% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Rezolute's chief executive and what were they paid?
Nevan Charles Elam was paid $5,711,410 in total compensation as Chief Executive Officer for fiscal 2026. Elam's total moved 100.3% higher from the $2,851,109 reported for fiscal 2025.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Nevan Charles Elam
Chief Executive Officer
◇◇—◇——◇◇
Brian Roberts
Chief Medical Officer
◇◇—◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Nevan Charles Elam
Chief Executive Officer
◇◇————◇◇
Brian Roberts
Chief Medical Officer
◇◇————◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Nevan Charles Elam
Chief Executive Officer
◇◇◇———◇◇
Brian Roberts
Chief Medical Officer
◇◇◇———◇◇
Daron Evans
Chief Financial Officer
◇◇◇———◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Nevan Charles Elam
Chief Executive Officer
◇◇◇◇——◇◇
Daron Evans
Chief Financial Officer
◇◇◇◇——◇◇
Brian Roberts
Chief Medical Officer
◇◇◇◇——◇◇
Fiscal 2026
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Nevan Charles Elam
Chief Executive Officer
◇◇◇◇——◇◇
Sunil Karnawat
Chief Commercial Officer
◇◇◇◇——◇◇
Brian Roberts
Chief Medical Officer
◇◇◇◇——◇◇
Daron Evans
Chief Financial and Business Officer
◇◇◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Brian RobertsRSU——————◇
Daron EvansRSU——————◇
Nevan Charles ElamRSU——————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2026 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Nevan Charles ElamRSU◇◇——
Option◇—◇November 19, 2035
RSU◇◇——
RSU◇◇——
Option◇—◇February 16, 2035
Option◇—◇January 23, 2034
Option◇—◇June 10, 2035
Brian RobertsRSU◇◇——
Option◇—◇November 19, 2035
RSU◇◇——
RSU◇◇——
Option◇—◇January 23, 2034
Option◇—◇February 16, 2035
Option◇—◇June 10, 2035
Daron EvansOption◇—◇January 23, 2029
RSU◇◇——
Option◇—◇September 23, 2034
RSU◇◇——
Option◇—◇November 19, 2035
RSU◇◇——
Option◇—◇February 16, 2035
Option◇—◇June 10, 2035
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2026
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gil Labrucherie
◇◇◇———◇
Wladimir Hogenhuis, M.D
◇◇◇———◇
Nerissa Kreher, M.D
◇◇◇———◇
Philippe Fauchet
◇◇◇———◇
Erik Harris
◇◇◇———◇
Young-Jin Kim
◇◇◇———◇
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Nevan Charles Elam (Chief Executive Officer), FY2026 total compensation $5,711,410 (base salary $655,000) [exec_comp, SEC accession 0001104659-26-117868, filed 2026-10-21]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Rezolute files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Rezolute disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Rezolute's disclosed peer group is defensible, who names Rezolute back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
153 figures on this page, cited to the filing that reported them.
153 cited to the filing

Documents cited

  1. 0001104659-26-117868
  2. 0001104659-25-097509
    EXECUTIVE COMPENSATION · Summary Compensation Table
  3. 0001104659-24-046889
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Rezolute executive compensation, FY2022–FY2026.” https://intel.velarion.ai/comp/RZLT (accessed 2026).
Short form: data: Velarion

The Rezolute brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Rezolute and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy